Financing ·
MapLight Therapeutics entered into a Securities Purchase Agreement for a $150 million private placement, selling…
MPLTMapLight Therapeutics, Inc.
MapLight Therapeutics entered into a Securities Purchase Agreement for a $150 million private placement, selling 9,197,887 shares of common stock and pre-funded warrants to purchase 3,983,168 additional shares at a price of $11.38 per share. The company also reported Q2 2026 financial results, including a net loss of $60.2 million and R&D expenses of $53.4 million, while holding $351.3 million in cash as of June 30, 2026. Clinically, the company announced positive Phase 2 ZEPHYR trial results for its schizophrenia candidate ML-007C-MA, which met its primary endpoint and supports advancement into a registrational Phase 3 ZEPHYR-2 trial. MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders.